drugset / Trial / NCT07497776

Atorvastatin Therapy in the Treatment of Dyslipidemia in Children With Steroid Sensitive Nephrotic Syndrome

NCT07497776 ↗

Non-randomizedParallel-groupOpen-labelSupportive care

Summary

To evaluate the effectiveness and safety of Atorvastatin therapy in children with dyslipidemia in steroid sensitive nephrotic syndrome.

Timeline

Start
2024-01-27
Primary completion
2025-08-30
Completion
2025-10-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Atorvastatin Small molecule 10 mg —

Indications